Principia Biopharma, a Sanofi Company
10
0
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
20.0%
2 terminated/withdrawn out of 10 trials
77.8%
-8.7% vs industry average
20%
2 trials in Phase 3/4
71%
5 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
Role: lead
A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)
Role: lead
Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants
Role: lead
Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants
Role: lead
Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis
Role: lead
A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)
Role: lead
Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects
Role: lead
A Study of PRN1008 in Patients With Pemphigus
Role: lead
A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
Role: lead
A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma
Role: lead
All 10 trials loaded